This phenomenon ultimately resulted in a superior sensitization to chemotherapy of TNBC cells, without affecting the ER+ BC cells (Fig. 3G), suggesting that the presence of a TP53 mutation could render TNBC cells more vulnerable to Sam68 knockdown and the chemotherapy-induced DNA-damage [33, 39]. Here, TP53 is linked to breast cancer.